We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mobile Testing Platform Performs World's Fastest Multiplex PCR and RT-PCR Analysis

By LabMedica International staff writers
Posted on 29 Jun 2022

Polymerase Chain Reaction (PCR) is an enzymatic amplification technique that produces a large number of identical copies of a DNA or RNA fragment and visualizes it by fluorescence. More...

This very fast, sensitive and sequence-specific technique is much more efficient than traditional culture-based diagnostic methods, which suffer from long delays in obtaining results (from several days to several weeks). This is currently the most relevant method for rapid detection of genetic sequences in a sample, for example those of bacteria or viruses causing infectious diseases. In addition to classical PCR, there are several other types of PCR such as RT-PCR (reverse transcription PCR), qPCR (quantitative PCR), dPCR (digital PCR) and ddPCR (droplet digital PCR). Now, a new techniques named hcPCR (high content PCR), combines the advantages of qPCR and dPCR, in order to detect a large number of targets per test (multiplexing) and obtain the maximum amount of information in record time.

The hcPCR technique has been developed at BforCure (Paris, France) with Chronos Dx, its mobile, easy-to-use PCR/RT-PCR testing tool that delivers in vitro diagnosis of many infectious diseases in less than 15 minutes. While real-time PCR or RT-PCR typically takes 35 minutes to one hour to detect genetic material, BforCure's Chronos Dx platform performs multiplex PCR and RT-PCR analysis in record time. With the company’s Bflash+ range of kits optimized for research purposes, it is even possible to obtain accurate test results in less than five minutes.

Chronos Dx is based on a combination of microfluidic and optical technologies, which allows for ultra-fast temperature changes in the reaction mixture, reduced PCR cycle times and the detection of multiple genetic targets present in a sample, all in a single test (multiplexing principle). Chronos Dx enables ultra-fast PCR tests to be performed on a wide range of infectious diseases (respiratory, digestive and sexually transmitted). The infectious disease PCR testing tool offers a reliable and rapid response to the needs of laboratories regarding the detection of microorganisms, whether in the medical, environmental or industrial fields. Mobile, easy to use and connected, the Chronos Dx platform can be directly used in delocalized "satellite laboratories", as close as possible to the needs of healthcare professionals. It allows medical laboratories to manage urgent samples by performing unit analyses of numerous contagious pathologies, in order to accelerate patient care.

Related Links:
BforCure 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.